Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

This is a video synopsis/summary of a panel discussion involving a multidisciplinary team of experts: Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD. In this segment, the focus shifts to the initiation of biosimilars, particularly for patients who have never been prescribed the originator biologic.

Haumschild begins the conversation by underscoring the significance of the patient perspective in initiating biosimilars. He emphasizes the role of shared decision-making in this context, acknowledging that discussions might differ when initiating someone who has never received the reference biologic compared with someone who has experience with it.

Strand, an authoritative voice in rheumatology, offers insights into best practices for initiating biosimilars in patients unfamiliar with the reference biologic. She emphasizes the importance of shared decision-making and anticipates scenarios where providers may need to make informed decisions on behalf of patients. Strand highlights the critical role of explaining biosimilars comprehensively to mitigate the nocebo effect, emphasizing the need for patient education.

Video synopsis is AI-generated and reviewed by editorial staff.